DS-8201 is a novel HER2-targeted antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor [11], which has anti-cancer efficacy in clinical trials and anti-tumor immunity in mouse models [12]. The gene discussed is ERBB2; the disease is cancer.